Early changes of nerve integrity in preclinical carriers of hereditary transthyretin Ala117Ser amyloidosis with polyneuropathy-Reference-Cited by-同舟云学术

Early changes of nerve integrity in preclinical carriers of hereditary transthyretin Ala117Ser amyloidosis with polyneuropathy

Published:2021-01-09 Issue:3 Volume:28 Page:982-991
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Chiang Ming‐Chang¹,Yeh Ti‐Yen²,Sung Jia‐Ying³,Hsueh Hsueh‐Wen⁴^ORCID,Kao Yi‐Hui⁴,Hsueh Sung‐Ju⁴,Chang Kai‐Chieh⁴^ORCID,Feng Fang‐Ping⁴,Lin Yea‐Huey⁴,Chao Chi‐Chao⁴^ORCID,Hsieh Sung‐Tsang²⁴⁵⁶⁷^ORCID

Affiliation:

1. Department of Biomedical Engineering National Yang‐Ming University Taipei Taiwan

2. Department of Anatomy and Cell Biology National Taiwan University College of Medicine Taipei Taiwan

3. Department of Neurology, Wan Fang Hospital Taipei Medical University Taipei Taiwan

4. Department of Neurology National Taiwan University Hospital Taipei Taiwan

5. Graduate Institute of Brain and Mind Sciences National Taiwan University College of Medicine Taipei Taiwan

6. Graduate Institute of Clinical Medicine National Taiwan University College of Medicine Taipei Taiwan

7. Center of Precision Medicine National Taiwan University College of Medicine Taipei Taiwan

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ene.14698

Reference43 articles.

1. Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease

2. Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser

3. Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between late- and early-onset cases in Portugal

4. Transthyretin-Related Familial Amyloidotic Polyneuropathy

5. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and biochemical characterization of asymptomatic carriers and symptomatic patients with hereditary transthyretin amyloidosis caused by TTR V30L mutation;Neurological Sciences;2024-09-14

2. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study;Journal of the Formosan Medical Association;2024-09

3. Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China;Amyloid;2024-07-31

4. Amyloid Neuropathy: From Pathophysiology to Treatment in Light‐Chain Amyloidosis and Hereditary Transthyretin Amyloidosis;Annals of Neurology;2024-06-24

5. Axonal excitability as an early biomarker of nerve involvement in hereditary transthyretin amyloidosis;Clinical Neurophysiology;2024-03